Ingenia Therapeutics Inc KRDR
950260
Company Profile
Business description
Ingenia Therapeutics Inc is a clinical-stage biotech company developing therapeutic antibody candidates for microvascular disorders and chronic diseases. Its programs focus on indications associated with damaged capillaries and aims to restore capillary function by modulating endothelial cell signaling pathways. The company's pipeline includes IGT-427, IGT-303, IGT-302, IGT-532, etc.
Contact
490 Arsenal Way
Suite 100B
WatertownMA02472
USAT: +1 617 440-2500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,475.66 | 22.57 | 0.27% |
| DAX 40 | 26,090.51 | 107.47 | 0.41% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,779.35 | 31.19 | 0.29% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,641.16 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |